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Abstract
The aim of the present study was to examine the associations between the maternal intake of fatty acids during pregnancy and the risk of
preclinical and clinical type 1 diabetes in the offspring. The study included 4887 children with human leucocyte antigen (HLA)-conferred
type 1 diabetes susceptibility born during the years 1997–2004 from the Finnish Type 1 Diabetes Prediction and Prevention Study. Maternal
diet was assessed with a validated FFQ. The offspring were observed at 3- to 12-month intervals for the appearance of type 1 diabetes-
associated autoantibodies and development of clinical type 1 diabetes (average follow-up period: 4·6 years (range 0·5–11·5 years)).
Altogether, 240 children developed preclinical type 1 diabetes and 112 children developed clinical type 1 diabetes. Piecewise linear
log-hazard survival model and Cox proportional-hazards regression were used for statistical analyses. The maternal intake of palmitic
acid (hazard ratio (HR) 0·82, 95 % CI 0·67, 0·99) and high consumption of cheese during pregnancy (highest quarter v. intermediate
half HR 0·52, 95 % CI 0·31, 0·87) were associated with a decreased risk of clinical type 1 diabetes. The consumption of sour milk products
(HR 1·14, 95 % CI 1·02, 1·28), intake of protein from sour milk (HR 1·15, 95 % CI 1·02, 1·29) and intake of fat from fresh milk (HR 1·43, 95 %
CI 1·04, 1·96) were associated with an increased risk of preclinical type 1 diabetes, and the intake of low-fat margarines (HR 0·67, 95 % CI
0·49, 0·92) was associated with a decreased risk. No conclusive associations between maternal fatty acid intake or food consumption during
pregnancy and the development of type 1 diabetes in the offspring were detected.
Key words: Pregnancy: Fatty acids: Type 1 diabetes: Foods: Children: Cohort studies
Finland has the world’s highest, and still increasing, incidence
of type 1 diabetes, with the increase being particularly
conspicuous among children aged below 5 years(1). Type 1
diabetes develops as the result of an immune-mediated
inflammatory reaction that destroys b-cells in the pancreatic
islets(2). Available data suggest that type 1 diabetes is caused
by a complex interplay between intestinal microbiota, gut
permeability and mucosal immunity(2). Prenatal modulation
of the gut is dependent on which factors the fetus encounters
via the placenta(3). Accordingly, maternal nutrition during
*Corresponding author: S. Niinisto¨, email sari.niinisto@thl.fi
Abbreviations: DIPP, The Finnish Type 1 Diabetes Prediction and Prevention Study; E%, percentage of total energy intake; ICA, islet cell antibodies.
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pregnancy may modulate the development of the gut immune
system in the offspring. Maternal fatty acid status during preg-
nancy influences the fatty acid status of the fetus and newborn
infant(4). The fatty acids may influence immune programming
in many ways, e.g. by altering the lipid composition of fetal
cell membranes, cellular metabolism, eicosanoid synthesis and
gene expression regulation(4).
Epidemiological studies have suggested that the consumption
of n-3 fatty acid-rich cod-liver oil during pregnancy or infancy
might help in the prevention of the development of type 1
diabetes(5,6). In contrast, in a US cohort, maternal n-3 and n-6
fatty acid intake has been shown to be not associated with the
appearance of islet autoimmunity in the offspring(7), and in a
Norwegian cohort study, maternal serum concentrations of
n-3 fatty acids during pregnancy have been reported to be not
associated with the risk of clinical type 1 diabetes in the
offspring(8). By contrast, in a US cohort, the intake of n-3 fatty
acids and their content in erythrocyte membranes in children
have been shown to be inversely associated with b-cell auto-
immunity(9). Animal studies have also indicated a protective
effect of n-3 fatty acids(10,11).
There are only a few studies that have considered the effect
of various fatty acids on the development of type 1 diabetes.
In our previous nested case–control analysis in children,
serum fatty acid biomarkers of milk consumption have been
shown to be positively associated, and linoleic acid inversely
associated, with the risk of advanced b-cell autoimmunity at
or close to the time of seroconversion(12). In our recent
study in children, we have found that the intake of fat from
all milk products is associated with a higher risk of preclinical
type 1 diabetes(13). Lipid-induced impairment of b-cell
function (lipotoxicity) has been well established both in vitro
and in vivo in animal models in the pathogenesis of type 2 dia-
betes(14). This raises the question of whether lipotoxicity is
involved in the pathogenesis of type 1 diabetes as well. By
contrast, MUFA have been shown to protect b-cells in some
in vitro studies(15).
In the present study, we evaluated the intake of fatty acids
and foods important in relation to fatty acid intake among
pregnant Finnish women and assessed associations with the
development of preclinical and clinical type 1 diabetes in
their offspring.
Methods
Participants
The present investigation is part of the Finnish Type 1
Diabetes Prediction and Prevention (DIPP) Study, which is a
large prospective, population-based birth cohort study of
Finnish children at an increased genetic risk of type 1 diabetes.
Increased human leucocyte antigen (HLA)-conferred disease
susceptibility is defined by a high-risk genotype (HLA-DQB1
*02/*0302) or a moderate-risk genotype (HLA-DQB1*0302/x,
where x ¼ other than *02,*0301 or *0602).Details of the genetic
screening methods and enrolment criteria have been published
previously(16). The present study was conducted according to
the guidelines laid down in the Declaration of Helsinki, and all
procedures involving human subjects were approved by the
Ethical Committees of the University Hospitals of Oulu and
Tampere, Finland. Written informed consent was obtained
from all the subjects.
The study population comprised 5605 children with HLA-
conferred susceptibility to type 1 diabetes. They were born
in Tampere or Oulu University Hospital between October
1997 and beginning of September 2004 (72 % of those invited).
FFQ were completed by the mothers of 4887 children during
pregnancy (87 %).
Assessment of maternal nutrition
The participants completed a validated 181-item semi-quanti-
tative FFQ concerning their habitual diet during 1 month. The
mothers were asked about their food consumption during the
eighth month of pregnancy (the month preceding maternity
leave in Finland). If more than ten of the 181 food frequency
questions were not answered, the FFQ was excluded (n 53).
The FFQ contained questions about the frequency (number of
times per d, week or month) and amount of foods consumed,
in units of common serving sizes. In addition, the FFQ contained
questions related to what type of fat was used in cooking and
baking and in salad dressings as well as questions related to
the extent of home baking. The individual type and quantity
of fat were taken into account when calculating food and nutri-
ent intakes. FFQ content, validity anddata processing have been
described earlier(17). Information on the intake of fatty acids
from all kinds of supplements throughout pregnancy was
requested. Sociodemographic and other factors, including
maternal education and diabetes in close relatives, were
recorded using a structured questionnaire completed by the
parents after delivery.
Autoantibody assays and definition of outcome
The DIPP children were monitored for the appearance of
signs of b-cell autoimmunity by analysing primarily islet cell
antibodies (ICA). If a child tested positive for ICA, all his or
her samples obtained from birth were analysed for insulin
autoantibodies, autoantibodies to 65 kDa isoform of glutamic
acid decarboxylase and antibodies to tyrosine phosphatase-
related islet antigen 2. Autoantibody samples were obtained
during each of the study centre visits, which were scheduled
to take place at the age of 3, 6, 12, 18 and 24 months and sub-
sequently at an interval of 12 months. If the child became
positive for ICA, the interval between visits was shortened to
3 months. The autoantibodies were analysed in the Research
Laboratory, Department of Pediatrics, University of Oulu.
ICA, insulin autoantibodies, autoantibodies to 65 kDa isoform
of glutamic acid decarboxylase and autoantibodies to tyrosine
phosphatase-related islet antigen 2 levels were quantified as
described previously(18).
We defined preclinical type 1 diabetes as being repeatedly
positive for ICA and one or more of the three other autoanti-
bodies analysed. Altogether, 283 of the 5605 (5·0 %) children
seroconverted to repeated ICA positivity and positivity to
one of the three other autoantibodies during this period at
S. Niinisto¨ et al.896
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a mean age of 3·6 (range 0·5–10·0) years. Of the children, 145
(2·6 %) had progressed to clinical type 1 diabetes at a mean
age of 4·6 (range 0·5–11·5) years. Among the children who
progressed to clinical type 1 diabetes, 103 had been repeat-
edly positive for ICA and at least one other autoantibody.
However, fifteen of the remaining forty-two children who pro-
gressed to type 1 diabetes had or had had one or more auto-
antibodies before or at the time of diagnosis. Moreover, ten
children who developed type 1 diabetes had been persistently
seronegative, with their last blood sample being drawn at a
mean age of 4·0 (range 0·3–7·7) years before diagnosis. A
total of seventeen children were not subjected to any autoanti-
body analysis before the diagnosis of diabetes. Thus, preclini-
cal type 1 diabetes endpoint was defined as the first
occurrence of either (1) repeated positivity for ICA in combi-
nation with positivity for one or more of the autoantibodies
analysed or (2) clinical type 1 diabetes. Due to missing
maternal FFQ data, statistical analyses were carried out with
240 preclinical and 112 clinical type 1 diabetes endpoints.
Statistical analyses
The endpoint of preclinical type 1 diabetes is interval cen-
sored and possibly dependent on siblings. To accommodate
this structure, a piecewise linear log-hazard survival model
was used to analyse the associations of fatty acid intake and
food consumption with the risk of preclinical type 1 diabetes,
assuming linear log-hazards in the intervals 0–1·99, 2–3·99
and .4 years. The results were not sensitive to the particular
choice of intervals used. Observation intervals beyond
positivity did not contribute to the analyses. The models
were fitted using maximum likelihood in SAS PROC
NLMIXED, with standard errors of the estimates derived
from the observed information matrix. Random effects for
family were introduced to accommodate familial dependence,
and these were assumed to follow a normal distribution. The
proportionality of the hazards was tested by adding linear
interaction terms of the exposure variables with time to the
models. To illustrate such time-varying effects, the endpoint
analyses were carried out in two settings. First, all the data
were used in the analyses. Second, data that included end-
point information only up to 3 years of age were used.
There was no interval censoring in the diagnosis of clinical
type 1 diabetes. Therefore, the associations of fatty acid
intake and food consumption with the risk of clinical disease
were analysed by Cox proportional-hazards regression.
Fatty acid variables were adjusted for energy intake by the
residual method(19) after logarithmic transformation. Food
variables were adjusted for energy intake by adding energy
intake as a covariate to the survival model. Fatty acid and
food variables were used as both continuous and categorical
(the latter defined by falling into intervals given by the first
and the third sample quartile) explanatory variables in the
analyses. Some food variables were dichotomised because of
a high proportion of non-users. If there is no indication
of a non-linear association between dietary variables and
endpoint, only results for continuous covariates are presented.
Otherwise, results for categorical variables are presented. In
addition to energy-adjusted fatty acid variables, analyses
were carried out for the relative proportions of fatty acids
(the percentages of total fatty acid intake). We also separately
analysed the intakes of fat and protein from milk products.
The possible confounding by background characteristics
(hospital of birth, familial diabetes and maternal vocational
education) was controlled by adding background variables
as covariates to the survival model; SAS version 9.2 (SAS
Institute) was used in the analyses. Statistical significance
was taken as less than 5 %.
Results
The characteristics of the study children are given in Table 1.
The maternal average daily intake of fatty acids from foods
and mean consumption of foods during pregnancy are given
in Tables 2 and 3, respectively. The number of users of sup-
plements containing fatty acids was small (n 81, 1·7 % of all
Table 1. Characteristics of the study participants
(Number of participants and percentages)
Distribution
With endpoint preclinical
type 1 diabetes
With endpoint type 1
diabetes
Characteristics n Percentage of total n Percentage of total n Percentage of total
Total n 4887 100 240 4·9 112 2·3
Genetic risk group
High risk (DQB1*02/*0302) 961 19·7 77 8·0 39 4·1
Moderate risk (DQB1*0302/x*) 3926 80·3 163 4·2 73 1·9
Familial diabetes
Yes 285 5·8 32 11·2 19 6·7
No 4421 90·5 202 4·6 91 2·1
Missing data 181 3·7 6 3·3 2 1·1
Maternal education
None 297 6·1 27 9·1 11 3·7
Vocational school/training 1292 26·4 58 4·5 22 1·7
Upper secondary/vocational 2067 42·3 88 4·3 46 2·2
Academic 1103 22·6 60 5·4 29 2·6
Missing data 128 2·6 7 5·5 4 3·1
*x not equal to *02, *0301 and *0602.
Maternal fatty acid intake and diabetes risk 897
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women). Thus, intakes of fatty acids only from food sources are
presented and used in the aetiological analysis. The maternal
mean daily intake of total fatty acids was 32·8 % of energy
intake (E%), SFA 14·4 E%, MUFA 11·7 E%, PUFA 4·7 E%, n-3
PUFA 1·0 E% and n-6 PUFA 3·5 E%. Fresh and sour milk,
cheese, butter and butter-oil spreads were the most important
sources of SFA, the most important of which were myristic, pen-
tadecanoic and palmitic acids (Table 2). Red meat and meat
products were the main sources of palmitoleic acid (both n-9
and n-7), stearic acid, oleic acid, cis-vaccenic acid and arachi-
donic acid. Linoleic acid and a-linolenic acid were derived
mainly from oils and EPA and DHA from fish.
The maternal intake of saturated palmitic acid (HR 0·82,
95 % CI 0·67, 0·99; P¼0·039) was weakly associated with
a decreased risk of clinical type 1 diabetes (Table 4). For
the endpoint clinical type 1 diabetes, interactions between
fatty acids and time were significant for the following fatty
acids: palmitoleic acid isomers 16 : 1n-7 (P¼0·019) and
16 : 1n-9 (P¼0·014); EPA (P¼0·037); dihomo-g-linolenic acid
(P¼0·013). To illustrate these apparently time-varying effects,
analyses were carried out separately for children aged below 3
years. When the follow-up time was less than 3 years, mono-
unsaturated palmitoleic acid (16 : 1n-7) (HR 0·54, 95 % CI 0·36,
0·86; P¼0·014) was associated with a decreased risk of clinical
type 1 diabetes, but not during the overall follow-up period.
High consumption of cheese was associated with a decreased
risk of clinical type 1 diabetes (highest quarter v. intermediate
half HR 0·52 (95 % CI 0·31, 0·87)) (Table 3). The consumption
of sour milk was associated with an increased risk of preclinical
type 1 diabetes (HR 1·14, 95 % CI 1·02, 1·28), and the consump-
tion of low-fat margarines was associated with a decreased
risk (HR 0·67, 95 % CI 0·49, 0·92). No significant interactions
with time were detected for any of the foods, and results are
thus presented for only the whole period. The adjustment for
the putative confounding variables (genetic risk, hospital of
birth, familial diabetes and maternal vocational education)
modified the results slightly (Tables 3, 4 and 5).
To determine which fraction of milk products accounts for
the observed associations with the development of preclinical
or clinical type 1 diabetes, we separately examined the intakes
of fat and protein from milk products. High intakes of fat from
fresh milk (HR 1·43, 95 % CI 1·04, 1·96) and protein from sour
milk (HR 1·15, 95 % CI 1·02, 1·29) were associated with an
increased risk of preclinical type 1 diabetes (Table 5).
Discussion
In the present prospective cohort study with genetically
susceptible offspring, it was found that maternal diet during
pregnancy was weakly associated with the development of
preclinical and clinical type 1 diabetes. The maternal intake
of palmitic acid and consumption of cheese during pregnancy
were inversely associated with the development of clinical
type 1 diabetes. The consumption of sour milk products,
intake of protein from sour milk and intake of fat from fresh
milk products were associated with an increased risk of pre-
clinical type 1 diabetes, and the intake of low-fat margarines
was associated with a decreased risk.T
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Table 3. Associations of maternal food consumption during pregnancy with the risk of preclinical and clinical type 1 diabetes in the offspring*
(Mean values and standard deviations; hazard ratios (HR) and 95 % confidence intervals)
Preclinical type 1 diabetes (n 4887, n 240) Type 1 diabetes (n 4887, n 112)
Food group
(g/d per times per week) Mean SD HR† 95 % CI P‡
Adjusted
HR§ 95 % CI P‡ HR† 95 % CI P‡
Adjusted
HR§ 95 % CI P‡
Cows’ milk products
(continuous) (g)
856 422 1·05 0·91, 1·21 0·521 1·02 0·88, 1·20 0·754 1·01 0·81, 1·25 0·943 1·01 0·81, 1·13 0·921
Fresh milk (g) 526 369
Lowest quarter: ,213 0·94 0·69, 1·28 0·94 0·68, 1·30 0·87 0·56, 1·36 0·88 0·56, 1·38
Intermediate half 1 0·421 1 0·196 1 0·071 1 0·037
Highest quarter: .760 0·81 0·58, 1·12 0·73 0·51, 1·04 0·56 0·33, 0·94 0·51 0·30, 0·88
Cheese (g) 65 46
Lowest quarter: ,31 0·82 0·60, 1·13 0·78 0·56, 1·09 0·65 0·40, 1·04 0·61 0·38, 1·00
Intermediate half 1 0·100 1 0·127 1 0·015 1 0·023
Highest quarter: .86 0·71 0·51, 0·99 0·74 0·52, 1·04 0·52 0·31, 0·87 0·55 0·33, 0·94
Sour milk (continuous) (g) 231 199 1·14 1·02, 1·28 0·030 1·16 1·03, 1·30 0·024 1·14 0·96, 1·35 0·155 1·15 0·97, 1·37 0·397
Butter and butter-oil spreads
(continuous) (g)
15 15 0·92 0·80, 1·07 0·293 0·96 0·83, 1·11 0·540 0·90 0·73, 1·12 0·330 0·92 0·74, 1·14 0·421
Low-fat margarines (g) 2·5 6
Users v. non-users 0·67 0·49, 0·92 0·010 0·66 0·48, 0·91 0·009 0·70 0·44, 1·10 0·104 0·66 0·41, 1·05 0·066
High-fat margarines (g) 7 13
Users v. non-users 1·12 1·00, 1·26 0·378 1·12 0·85, 1·46 0·422 1·16 0·80, 1·69 0·431 1·18 0·81, 1·73 0·391
Oil (continuous) (g) 11 7 0·96 0·84, 1·11 0·677 0·96 0·82, 1·11 0·557 0·96 0·78, 1·17 0·661 1·03 0·83, 1·28 0·804
Red meat and meat products
(continuous) (g)
127 61 1·10 0·94, 1·28 0·231 1·09 0·93, 1·27 0·308 1·15 0·92, 1·44 0·213 1·16 0·92, 1·45 0·208
Poultry (continuous) (g) 37 32 0·97 0·85, 1·12 0·718 1·02 0·89, 1·17 0·805 0·98 0·79, 1·20 0·831 1·03 0·83, 1·27 0·810
Fatty fishk (continuous)
(times per week)
1·3 1·3 0·89 0·76, 1·03 0·108 0·91 0·78, 1·06 0·193 0·92 0·74, 1·14 0·414 0·91 0·73, 1·14 0·411
Lean fish{ (continuous)
(times per week)
0·7 0·7 1·00 0·88, 1·14 0·966 0·97 0·85, 1·12 0·687 1·05 0·88-1·26 0·604 0·99 0·81, 1·20 0·883
* For continuous food variables, HR describes the change in risk, when the food variable is changed by an amount corresponding to its standard deviation. For categorical food variables, reference category is the intermediate half,
and for dichotomised variables, reference category is the non-users.
† Model was adjusted for maternal energy intake.
‡ Likelihood ratio test was used to test whether the model with and without the food variables differed.
§ Model was adjusted for maternal energy intake, genetic risk, hospital of birth, familial diabetes and maternal vocational education.
kSalmon, rainbow trout, Baltic herring, mackerel, lavaret, trout, European cisco, pike-perch, flounder, bream, rosefish, herring, anchovy and tuna.
{Fish fingers, frozen fish, perch, northern pike, burbot, shrimps and shell.
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Table 4. Associations of maternal fatty acid intake during pregnancy with the risk of preclinical and clinical type 1 diabetes in the offspring*
(Hazard ratios (HR) and 95 % confidence intervals)
Preclinical type 1 diabetes Type 1 diabetes
All (n 4887, n 240) All (n 4887, n 240) All (n 4887, n 112) All (n 4887, n 112)
Fatty acids (g/mg) HR 95 % CI P† Adjusted HR‡ 95 % CI P† HR 95 % CI P† Adjusted HR‡ 95 % CI P†
Total fatty acids (g) 0·92 0·81, 1·05 0·247 0·92 0·80, 1·05 0·224 0·86 0·71, 1·05 0·134 0·86 0·71, 1·05 0·143
SFA (g) 0·90 0·79, 1·03 0·127 0·91 0·79, 1·04 0·163 0·83 0·68, 1·01 0·056 0·84 0·69, 1·03 0·087
Myristic acid (14 : 0) (mg) 0·90 0·79, 1·03 0·133 0·92 0·81, 1·06 0·246 0·82 0·67, 1·00 0·041 0·86 0·71, 1·05 0·132
Pentadecanoic acid (15 : 0) (mg) 0·91 0·80, 1·04 0·172 0·93 0·81, 1·06 0·172 0·84 0·69, 1·03 0·083 0·87 0·71, 1·06 0·153
Palmitic acid (16 : 0) (mg) 0·89 0·79, 1·02 0·099 0·90 0·79, 1·03 0·134 0·82 0·67, 0·99 0·039 0·84 0·69, 1·02 0·074
Stearic acid (18 : 0) (mg) 0·91 0·80, 1·03 0·150 0·91 0·79, 1·04 0·162 0·84 0·69, 1·03 0·085 0·85 0·70, 1·04 0·120
MUFA (g) 0·96 0·84, 1·09 0·551 0·96 0·82, 1·08 0·404 0·93 0·76, 1·12 0·427 0·91 0·75, 1·11 0·348
Palmitoleic acid (16 : 1n-7) (mg) 0·91 0·79, 1·03 0·145 0·93 0·81, 1·07 0·307 0·90 0·74, 1·09 0·265 0·95 0·78, 1·15 0·571
Palmitoleic acid (16 : 1n-9) (mg) 0·96 0·84, 1·10 0·562 0·98 0·86, 1·12 0·753 1·02 0·84, 1·24 0·833 1·05 0·87, 1·26 0·649
Oleic acid (18 : 1n-9) (mg) 0·93 0·82, 1·06 0·296 1·02 0·89, 1·16 0·802 0·92 0·76, 1·11 0·386 0·99 0·82, 1·20 0·926
Cis-vaccenic acid (18 : 1n-7) (mg) 0·95 0·84, 1·08 0·456 10·03 0·84, 1·08 0·693 0·97 0·80, 1·16 0·707 1·04 0·87, 1·26 0·660
PUFA (g) 1·01 0·89, 1·14 0·887 0·96 0·83, 1·09 0·502 1·00 0·83, 1·20 0·975 0·98 0·80, 1·19 0·798
n-3 (g) 0·97 0·86, 1·10 0·685 0·97 0·86, 1·10 0·685 1·02 0·85, 1·23 0·802 0·99 0·82, 1·20 0·917
a-Linolenic acid (18 : 3n-3) (mg) 0·99 0·87, 1·12 0·856 0·97 0·85, 1·10 0·607 1·02 0·85, 1·22 0·848 0·98 0·81, 1·19 0·844
EPA (20 : 5n-3) (mg) 0·94 0·82, 1·08 0·401 0·96 0·83, 1·11 0·560 1·03 0·86, 1·24 0·730 1·04 0·85, 1·26 0·719
DHA (22 : 6n-3) (mg) 0·96 0·84, 1·10 0·531 0·97 0·84, 1·12 0·708 1·04 0·87, 1·25 0·669 1·04 0·86, 1·27 0·687
n-6 (g) 1·02 0·90, 1·16 0·707 1·01 0·88, 1·15 0·910 1·00 0·83, 1·21 0·996 0·98 0·80, 1·19 0·219
Linoleic acid (18 : 2n-6) (mg) 1·01 0·89, 1·15 0·796 1·01 0·88, 1·15 0·942 1·00 0·83, 1·20 0·995 1·00 0·83, 1·20 0·995
Arachidonic acid (20 : 4n-6) (mg) 1·03 0·91, 1·17 0·608 1·04 0·92, 1·19 0·537 1·08 0·90, 1·30 0·397 1·08 0·90, 1·30 0·397
g-Linolenic acid (18 : 3n-6) (mg) 0·92 0·78, 1·09 0·310 0·93 0·81, 1·07 0·293 0·84 0·65, 1·10 0·187 0·84 0·65, 1·10 0·187
Dihomo-g-linolenic acid (20 : 3n-6) (mg) 0·96 0·84, 1·10 0·556 0·94 0·82, 1·08 0·384 1·01 0·84, 1·22 0·923 1·02 0·84, 1·22 0·874
Ratio of n-6:n-3 1·05 0·94, 1·18 0·407 1·06 0·94, 1·20 0·332 0·96 0·79, 1·17 0·698 0·98 0·81, 1·19 0·832
Conjugated linoleic acid (18 : 2n-6) (mg) 0·93 0·81, 1·06 0·757 0·94 0·82, 1·08 0·377 0·88 0·72, 1·07 0·186 0·89 0·73, 1·08 0·220
* Fatty acid variables used in statistical analyses were energy adjusted using Willett’s residual method. HR describes change in risk, when fatty acid variable is changed by an amount corresponding to its standard deviation. These
results are not adjusted for any potential confounders.
† Likelihood ratio test was used to test whether the model with and without the fatty acid variables differed.
‡ Model was adjusted for genetic risk, hospital of birth, familial diabetes and maternal vocational education.
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Table 5. Associations of maternal intake of fat and protein from dairy products during pregnancy with the risk of preclinical and clinical type 1 diabetes in the offspring*
(Hazard ratios (HR) and 95 % confidence intervals)
Preclinical type 1 diabetes (n 4887, n 240) Type 1 diabetes (n 4887, n 112)
Fat and protein from dairy products (g) HR† 95 % CI P‡ Adjusted HR§ 95 % CI P‡ HR† 95 % CI P‡ Adjusted HR§ 95 % CI P‡
Fat from
All cows’ milk products (continuous) 0·89 0·75, 1·06 0·197 0·91 0·76, 1·08 0·275 0·87 0·68, 1·12 0·265 0·90 0·70, 1·16 0·408
Fresh milk
Lowest quarter 1·35 0·98, 1·87 1·31 0·95, 1·82 1·62 1·04, 2·52 1·64 1·04, 2·59
Intermediate half 1 0·046 1 0·081 1 0·114 1 0·112
Highest quarter 1·43 1·04, 1·96 1·39 1·01, 1·92 1·16 0·72, 1·86 1·17 0·72, 1·90
Cheese (continuous) 0·86 0·74, 1·01 0·053 0·88 0·75, 1·03 0·101 0·89 0·71, 1·10 0·266 0·92 0·74, 1·15 0·459
Sour milk (continuous) 1·08 0·95, 1·22 0·280 1·07 0·94, 1·22 0·310 1·06 0·88, 1·28 0·549 1·06 0·88, 1·27 0·578
Protein from
All cows’ milk products (continuous) 0·94 0·80, 1·11 0·468 0·94 0·79, 1·11 0·480 0·92 0·73, 1·17 0·497 0·96 0·75, 1·22 0·713
Fresh milk
Lowest quarter 0·94 0·68, 1·29 0·94 0·68, 1·29 0·88 0·56, 1·37 0·88 0·56, 1·39
Intermediate half 1 0·340 1 0·155 1 0·077 1 0·045
Highest quarter 0·78 0·55, 1·09 0·71 0·50, 1·01 0·56 0·33, 0·95 0·52 0·30, 0·89
Cheese
Lowest quarter 0·92 0·67, 1·27 0·86 0·62, 1·19 0·80 0·51, 1·27 0·71 0·44, 1·15
Intermediate half 1 0·177 1 0·241 1 0·070 1 0·088
Highest quarter 0·72 0·51, 1·02 0·75 0·53, 1·07 0·56 0·34, 0·94 0·60 0·36, 1·01
Sour milk (continuous) 1·15 1·02, 1·29 0·030 1·16 1·03, 1·31 0·023 1·14 0·96, 1·36 0·147 1·16 0·98, 1·38 0·112
* For continuous fat and protein variables, HR describes change in risk, when the food variable is changed by an amount corresponding to its standard deviation. For categorical fat and protein variables, reference category is the
intermediate half.
† Model was adjusted for energy intake.
‡ Likelihood ratio test was used to test whether the model with and without the food variables differed.
§ Model was adjusted for maternal energy intake, genetic risk, hospital of birth, familial diabetes and maternal vocational education.
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The strength of the present study is the population-based
prospective cohort setting as well as the fact that the end-
points used comprised both preclinical type 1 diabetes and,
separately, clinical type 1 diabetes. The endpoint ‘preclinical
type 1 diabetes’ is strongly associated with clinical disease(20).
The FFQ used in the present study was validated against two
5 d food records, and it estimated the consumption of food
groups relatively well(17). The consumption of milk products
had very good validity (Pearson’s correlation coefficients for
different milk products varied between 0·58 and 0·86)(17).
The major limitation of the study is the high number of fatty
acids and food groups analysed. Altogether, we tested over
seventy associations. None of the associations was highly sig-
nificant and may be false positive and occur due to chance.
Therefore, the results must be interpreted with caution.
Another limitation is that the children’s diet during infancy
was not taken into account, because the food records of all
the children were not available. In the validation study, for
some important food sources of fat, the correlations measured
by FFQ and food records were low, as Pearson’s correlation
coefficients for the consumption of oils and low-fat spreads
were 0·22 and 0·25, respectively(17).
The present observation is the first epidemiological one
to indicate that the maternal intake of palmitic acid, which
reflects the consumption of certain milk products, and con-
sumption of cheese are inversely associated with clinical type 1
diabetes in the offspring. The results indicate that maternal
exposure to certain milk products during pregnancy might
induce tolerance to cows’ milk in genetically susceptible off-
spring. A previous study has shown that the maternal intake of
protein from cheese during pregnancy and maternal intake of
protein from fresh milk products and cheese during lactation
are marginally inversely associated with the humoral immune
responses to cows’ milk proteins in offspring with a high risk
of type 1 diabetes(21). An enhanced humoral immune response
to various cows’ milk proteins has been observed in infancy in
children who later were diagnosed with type 1 diabetes(22).
In contrast to the inverse associations between the maternal
intake of milk-related fatty acids and the risk of type 1 diabetes
in the offspring in the present study, our previous case–
control analysis in 315 children has shown that the fatty acid
biomarkers of milk consumption are directly associated with
the risk of islet autoimmunity at or before the time of sero-
conversion(12). Our newest findings in children were that the
consumption of fresh milk products and cows’ milk-based
infant formulas and the intake of fat from all milk products
and intake of protein from fresh milk products are weakly
associated with a higher risk of advanced preclinical type 1
diabetes(13). These findings support the hypothesis that the
direct exposure of children to cows’ milk leads to immu-
nisation or the results could be partly explained by possible
lipotoxicity. Several other case–control and cohort studies as
well as randomised trial findings also support the hypothesis
that cows’ milk is associated with the development of type 1
diabetes, although there are conflicting results also(23,24). Savi-
lahti & Saarinen(25) observed that very early exposure to cows’
milk in the maternity hospital may decrease the risk of type 1
diabetes in the offspring by the age of 8 years.
In the present study, the maternal intake of palmitoleic acid
(16 : 1n-7) during pregnancy was inversely associated with the
risk of clinical type 1 diabetes when the children were
observed up to the age of 3 years. An inverse association of
palmitoleic acid intake may reflect the maternal consumption
of meat or dairy products. The observation could also reflect
that the effect of palmitoleic acid may be protective in accord-
ance with some in vitro studies(15).
Type 1 diabetes has been shown to be associated with
increased inflammation, and n-3 fatty acids have been impli-
cated as anti-inflammatory agents, while n-6 acids fatty acids
have been shown to be pro-inflammatory agents(26). In line
with other cohort findings, the maternal intake of n-3 or n-6
fatty acids during pregnancy was not associated with the risk
of preclinical or clinical type 1 diabetes in the present study(7,8).
In accordance with our previous analyses using a smaller
dataset, the maternal intake of low-fat margarines during preg-
nancy was found to be associated with a decreased risk of pre-
clinical type 1 diabetes(27). In contrast to our earlier results(27),
butter was not associated with the risk of prediabetes and sour
milk was associated with an increased risk of prediabetes in
the present study. However, in the present study, the maternal
intake of protein from sour milk was also associated with an
increased risk of prediabetes.
The present findings that the maternal intake of fat from
fresh milk products is weakly associated with an increased
risk of advanced preclinical type 1 diabetes may indicate
lipotoxicity to be responsible for the pathogenesis of type 1
diabetes. However, palmitic acid intake exhibited a protective
association with the clinical type 1 diabetes endpoint.
In other analyses carried out in the cohort of the present
study, interesting findings emerged for fatty acids and other
immune-mediated endpoints, and these suggest that maternal
diet and fatty acid intake during pregnancy may influence the
development of the immune system in the offspring. High
maternal consumption of butter and a high ratio of n-6:n-3
fatty acids during pregnancy have been reported to be
associated with an increased risk of allergic rhinitis in the
offspring(28). The maternal intakes of a-linoleic acid (n-3),
total n-3 PUFA, SFA and palmitic acid during pregnancy
have been reported to be associated with a decreased risk
of asthma and that of arachidonic acid (n-6) with an increased
risk(29). These and present findings support the importance of
fatty acids when studying relationships between nutrition and
immune-mediated diseases.
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